Side effects and complications of amiodarone therapy

https://doi.org/10.1016/0002-8703(85)90238-8Get rights and content

Abstract

To assess the incidence of adverse effects associated with long-term amiodarone therapy, we reviewed the records of 217 consecutive patients who were treated for refractory arrhythmia. After an average of 11.8 months of therapy, one or more side effects occurred in 113 patients (52%). These were considered clinically significant in 42 patients (19.3%), mandating discontinuation of amiodarone in 18 (8.3%). The untoward reactions requiring discontinuation of amiodarone included thyroid dysfunction, visual disturbances, pulmonary infiltrates, ataxia, cardiac conduction abnormalities, and drug interactions. The mild side effects included corneal microdeposits, skin rashes, and gastrointestinal symptoms. There was a weak correlation between blood levels of amiodarone, the daily dose, and the cumulative dose (r = 0.23, p = 0.015). Drug levels were higher in symptomatic patients (p < 0.03), although they received lower doses of amiodarone. While amiodarone is associated with frequent side effects, they are generally mild and do not necessitate drug discontinuation. Careful monitoring of therapy is essential to detect the potentially serious adverse reactions which are encountered in nearly 20% of patients.

References (51)

  • S Sclarovsky et al.

    Amiodarone-induced polymorphous ventricular tachycardia

    Am Heart J

    (1983)
  • G Cui et al.

    Ventricular flutter during treatment with amiodarone

    Am J Cardiol

    (1983)
  • F Lustman et al.

    Amiodarone and neurological side effects

    Lancet

    (1974)
  • BD Kosowsky et al.

    Long-term use of procainamide following acute myocardial infarction

    Circulation

    (1973)
  • PJ Podrid et al.

    Congestive heart failure caused by oral disopyramide

    N Engl J Med

    (1980)
  • DM McCarthy

    Ranitidine or cimetidine

    Ann Intern Med

    (1983)
  • L Harris et al.

    Side effects of long-term amiodarone therapy

    Circulation

    (1983)
  • A Achilli et al.

    Amiodarone increases plasma digoxin concentrations

    Br Med J

    (1981)
  • U Martinowitz et al.

    Interaction between warfarin sodium and amiodarone

    N Engl J Med

    (1981)
  • F Andreasen et al.

    Pharmacokinetics of amiodarone after intravenous and oral administration

    Eur J Clin Pharmacol

    (1981)
  • Sas Institute Inc.,

    SAS user's guide: Statistics

    (1982)
  • CI Haffajee et al.

    Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias

    Circulation

    (1983)
  • JJ Heger et al.

    Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation

    N Engl J Med

    (1981)
  • SA Riley et al.

    Alveolitis after treatment with amiodarone

    Br Med J

    (1982)
  • SM Sobol et al.

    Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug

    Circulation

    (1982)
  • Cited by (188)

    • CLInical Profile and Side Effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study

      2022, Annals of Medicine and Surgery
      Citation Excerpt :

      Amiodarone is not indicated for persons with second or third-degree heart block who do not have pacemakers. Amiodarone should be avoided in those who have a baseline QTc prolongation [28,29]. Although retrospective investigations have shown that iodine or iodinated contrast agent allergies are not an absolute contraindication to amiodarone, the incidence of hypersensitivity reactions to amiodarone in people who have been diagnosed with iodine allergies should be closely monitored [30,31].

    • Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study

      2020, Heart Rhythm
      Citation Excerpt :

      Previous studies have generally been limited by sample size, however, using a large cohort with long-term follow-up and nationwide coverage, we did not find any associations between amiodarone therapy and incident cancers. Our results suggest that even though amiodarone is associated with a relatively high risk of organ toxicity, which manifests especially after prolonged treatment, this is not reflected in cancer occurrence in patients with AF.22,28,29 The major limitations of the study are inherent to the observational study design, the potential for bias, and the inability to draw causal conclusions.

    View all citing articles on Scopus

    Supported by the Rappaport International Cardiovascular Program and by Grant No. HL-07776 from the National Heart, Lung, and Blood Institute, National institutes of Health, United States Public Health Service, Bethesda, Md.

    View full text